Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
07/02/202408:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/02/202408:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/02/202408:05GlobeNewswire Inc.Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/02/202409:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/02/202408:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/02/202401:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:REGNRegeneron Pharmaceuticals Inc
03/02/202408:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/02/202408:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202423:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202422:30GlobeNewswire Inc.Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202422:00GlobeNewswire Inc.Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202408:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202408:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/02/202408:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/02/202408:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/01/202409:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
31/01/202401:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202423:00GlobeNewswire Inc.Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical ProgramsNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/01/202408:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REGNRegeneron Pharmaceuticals Inc
26/01/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/01/202408:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/01/202408:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/01/202406:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/01/202404:05PR Newswire (US)Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in AwardsNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/01/202404:00GlobeNewswire Inc.Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in AwardsNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/01/202408:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
19/01/202408:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
18/01/202408:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/01/202423:00GlobeNewswire Inc.Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot InvolvementNASDAQ:REGNRegeneron Pharmaceuticals Inc
09/01/202408:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN